Evidence map›Paper›PMID 29790971›Full record

ArticleJournal of the National Cancer Institute2019

Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia.

Slim Fellah, Yin T Cheung, Matthew A Scoggins, Ping Zou, Noah D Sabin, Ching-Hon Pui, Leslie L Robison, Melissa M Hudson, Robert J Ogg, Kevin R Krull

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. [Recent research on cognitive impairment in children with acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Brain Imaging in Pediatric Cancer Survivors: Correlates of Cognitive Impairment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Slim FellahDepartments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Yin T CheungEpidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
Matthew A ScogginsDepartments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Ping ZouDepartments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Noah D SabinDepartments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Ching-Hon PuiOncology, St. Jude Children's Research Hospital, Memphis, TN.
Leslie L RobisonEpidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
Melissa M HudsonEpidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
Robert J OggDepartments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.
Kevin R KrullEpidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.
St. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
MRI Scanner (3T) for Research in Catastrophic Diseases of ChildhoodS10RR029005 · NCRR · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI OGG, ROBERT J · 2010 to 2010
$2.8M
Risk for Psychopathology and Neurocognitive Impairment in Leukemia SurvivorsR01MH085849 · NIMH · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KRULL, KEVIN R · 2010 to 2014
$2.4M
NCI NIH HHS U01 CA195547NCRR NIH HHS S10 RR029005NIMH NIH HHS R01 MH085849
6 · The paper itself

Abstract

backgroundThe impact of contemporary chemotherapy treatment for childhood acute lymphoblastic leukemia on central nervous system activity is not fully appreciated.

methodsNeurocognitive testing and functional magnetic resonance imaging (fMRI) were obtained in 165 survivors five or more years postdiagnosis (average age = 14.4 years, 7.7 years from diagnosis, 51.5% males). Chemotherapy exposure was measured as serum concentration of methotrexate following high-dose intravenous injection. Neurocognitive testing included measures of attention and executive function. fMRI was obtained during completion of two tasks, the continuous performance task (CPT) and the attention network task (ANT). Image analysis was performed using Statistical Parametric Mapping software, with contrasts targeting sustained attention, alerting, orienting, and conflict. All statistical tests were two-sided.

resultsCompared with population norms, survivors demonstrated impairment on number-letter switching (P < .001, a measure of cognitive flexibility), which was associated with treatment intensity (P = .048). Task performance during fMRI was associated with neurocognitive dysfunction across multiple tasks. Regional brain activation was lower in survivors diagnosed at younger ages for the CPT (bilateral parietal and temporal lobes) and the ANT (left parietal and right hippocampus). With higher serum methotrexate exposure, CPT activation decreased in the right temporal and bilateral frontal and parietal lobes, but ANT alerting activation increased in the ventral frontal, insula, caudate, and anterior cingulate.

conclusionsBrain activation during attention and executive function tasks was associated with serum methotrexate exposure and age at diagnosis. These findings provide evidence for compromised and compensatory changes in regional brain function that may help clarify the neural substrates of cognitive deficits in acute lymphoblastic leukemia survivors.

Indexed as

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsAttention Deficit Disorder with HyperactivityBrainCancer SurvivorsChildExecutive FunctionFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleNeuropsychological TestsPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosis

Identifiers

PMID29790971
PMCPMC6376909
OpenAlexW2803108932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.